Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
To determine the pathologic complete response (pCR) rate in patients with cT1b-T2N0 GEA
treated with neoadjuvant pembrolizumab followed by surgical resection.